Hygrovest Ltd welcomes dosing of first patient by investment ValoTx in Phase I trial

Hygrovest Ltd (ASX:HGV, OTC:MMJJF) welcomes the dosing by its Finland-based investment Valo Therapeutics Oy (ValoTx) of the first patient in a Phase I trial...

Related Keywords

Heidelberg ,Baden Wüberg ,Germany ,Helsinki ,Eteläuomen Läi ,Finland ,Paul Higham ,Krankenhaus Nordwest ,Vincenzo Cerullo ,University Of Helsinki ,Hygrovest Ltd ,Safety Data Committee ,National Center ,Professor Vincenzo Cerullo ,Tumor Diseases ,Prof Guy Ungerechts ,